DexCom, Inc. is a global leader in continuous glucose monitoring systems, offering real-time solutions for diabetes management. Their flagship products, the G6 and G7 systems, track glucose levels non-invasively. Despite a 12.6% stock gain in the past year, recent market reaction to strong second-quarter results saw a 9.3% drop.

In the fiscal year 2025, DexCom is expected to grow bottom line by 25% to $2.05 per share. The company has a history of surpassing consensus estimates and has a “Strong Buy” consensus among 25 analysts. Price targets range from $102 to $125, indicating potential upside of 28.3% to 56.3%.

Analysts like Canaccord Genuity and Raymond James maintain “Buy” and “Strong Buy” ratings, with price targets around $102.60. DexCom’s market outlook remains stable, with positive growth projections and a strong consensus among analysts. The company continues to innovate in the evolving healthcare and medical device sectors.

Read more at Yahoo Finance: DexCom Stock: Analyst Estimates & Ratings